30 closest matches · ranked by relevance
Nasopharyngeal Carcinoma
Primary: 3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy — 100 participants with loco-regional control
Stage II Lymphoepithelioma of the Nasopharynx · Stage II Squamous Cell Carcinoma of the Nasopharynx · Stage III Lymphoepithelioma of the Nasopharynx
Primary: Number of Participants With Progression-free Survival (PFS) at 2 Years After Chemo-radiotherapy — 18; 4 Participants
Nasopharyngeal Carcinoma
Primary: Rate of Completion of All Adjuvant Immunotherapy — 100 percentage of participants
Nasopharyngeal Nonkeratinizing Carcinoma · Recurrent Nasopharynx Carcinoma · Stage III Nasopharyngeal Carcinoma AJCC v7
Primary: Confirmed Response Rate (Complete Response or Partial Response) Based on RECIST Version 1.1 — 20.5 percentage of patients with a response
Nasopharyngeal Carcinoma
Primary: Number of Participants With Acute Toxicity — 23 Participants
Nasopharyngeal Neoplasms
Primary: Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent…
Head and Neck Cancer · Oral Complications of Radiation Therapy · Radiation Toxicity
Primary: Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered — 9 participants
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
Nasopharyngeal Carcinoma
Primary: Overall Survival (OS) of Subjects With Advanced Nasopharyngeal Carcinoma. — 25; 24.9 Months — p=0.1942
Head and Neck Cancer
Primary: Survival Rate of Patients — 33 months
Nasopharyngeal Cancer
Primary: Progression Free Survival. — 6.3 Months
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Primary: Percentage of Patients With a Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the…
Nasopharyngeal Carcinoma
Primary: Progression-free Survival (PFS) as Per RECIST v 1.1 Using Central Assessment - Number of Participants With Progression or Death — 62; 32; 3; 1 Participants
Recurrent Lymphoepithelioma of the Nasopharynx · Recurrent Squamous Cell Carcinoma of the Nasopharynx · Stage IV Lymphoepithelioma of the Nasopharynx
Primary: Clinical Benefit Rate — 54.5 percentage of participants
Nasopharyngeal Carcinoma
Primary: Positive Nasopharynx Biopsy Results Detected by NBI System in Those Post-radiotherapy 8th Week NPC Patient — 14; 1; 20; 1 participants
Nasopharyngeal Neoplasms
Primary: Overall Survival (OS) — 17.2; 15.3 Months — p=0.2262
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 · Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Primary: Two Year Event-free Survival (EFS) — 0.87 Estimated probability
Nasopharyngeal Carcinoma
Primary: Objective Response Rate (ORR) Assess by Independent Review Committee (IRC) — 28.3 percentage of participants
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Dysphagia
Primary: The Change From Baseline and Cut Point VFSS in Velocity of Displacement of Hyoid Bone at 1 to 3 Months — 0.8; -0.4 cm/s
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Recurrent or Metastatic NPC
Primary: IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 — 8.2; 21.4 months
Head and Neck Cancer
Primary: Overall Response Rate — 0 patients
Squamous Cell Carcinoma of the Head and Neck · Carcinoma, Squamous Cell of the Head and Neck · Cancer of Head and Neck
Primary: Arm 1 and Arm 2: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site — 28; 8 Participants
Recurrent or Metastatic Nasopharyngeal Cancer
Primary: Progression-free Survival as Assessed by the Independent Review Committee (IRC) — 9.2; 7.4 Months
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Nasopharyngeal Neoplasms · Carcinoma
Primary: Number of Participants With Complete Response (CR) — 1; 0 participants — p=1.0000